Breast Cancer Treatment: A Review
暂无分享,去创建一个
[1] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[2] A. Giobbie-Hurder,et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.
[3] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[4] C. Hudis,et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[5] T. Julian,et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. , 2007, The Lancet. Oncology.
[6] M. Morrow,et al. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review , 2017, JAMA oncology.
[7] D. Cameron,et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. , 2015, The Lancet. Oncology.
[8] T. Julian,et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.
[9] EBCTCG (Early Breast Cancer Trialists' Collaborati. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials , 2014, The Lancet.
[10] M. Hurlbert,et al. Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. , 2014, Cancer epidemiology.
[11] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Kumthekar,et al. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. , 2018, Future oncology.
[13] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[14] T. Whelan,et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. , 2016, The New England journal of medicine.
[15] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[16] Laurence Collette,et al. Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .
[17] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[18] R. Peto,et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials , 2014, The Lancet.
[19] P. Fasching,et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R Peto,et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.
[21] C. Caldas,et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. , 2018 .
[22] F. Holmes,et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] I. Ellis,et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial , 2017, The Lancet.
[24] Ian Krop,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[26] A. Amini,et al. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[27] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[28] J. Berlin,et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Ruíz,et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.
[30] E. Winer,et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.
[31] Sung-Bae Kim,et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.
[32] Ming-Feng Hou,et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.
[33] M. Buyse,et al. Adjuvant Trastuzumab in HER 2-Positive Breast Cancer , 2011 .
[34] K. Holli,et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Press,et al. Molecular Oncology of Breast Cancer , 2018 .
[36] Anthony Fyles,et al. Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.
[37] C. Lawton. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial , 2012 .
[38] Mike Clarke,et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.
[39] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[40] E. Winer,et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.
[41] H. Earl,et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[43] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[44] H. Struikmans,et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.
[45] Joanne S Haviland,et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.
[46] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[47] H. Gómez,et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[49] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[50] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[51] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R Peto,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[53] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.
[54] S. Shak,et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] A. Giobbie-Hurder,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.
[56] C. Denkert,et al. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies , 2017, The Lancet.
[57] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[58] E. Winer,et al. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? , 2018, Clinical Cancer Research.
[59] Jay R. Harris,et al. Diseases of the Breast , 2014 .
[60] S. Loi,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[61] M. Ellis,et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). , 2017 .
[62] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[63] N. Campioni. [The physical examination of the breast]. , 1967, Il Policlinico. Sezione pratica.
[64] Jorge S Reis-Filho,et al. Triple-negative breast cancer. , 2010, The New England journal of medicine.
[65] K. Hunt,et al. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. , 2017, The oncologist.
[66] R. Peto,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.
[67] M. Ellis,et al. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[68] E. Perez,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[69] Marion Procter,et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.
[70] R. Mansel,et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.
[71] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[72] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[73] M. Duffy,et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). , 2017, European journal of cancer.
[74] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[75] P. Neven,et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Sung-Bae Kim,et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[77] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Alphonse G. Taghian,et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. , 2017, Practical radiation oncology.
[79] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] A. Jemal,et al. Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] W. Eiermann,et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.
[82] E. Winer,et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer , 2018, The New England journal of medicine.
[83] David Cameron,et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.
[84] F. Holmes,et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[86] Daniel F. Hayes,et al. 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.
[87] Ruth Etzioni,et al. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[88] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[91] B. Henderson,et al. Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer , 2015, Journal of Community Health.
[92] Laurence Collette,et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. , 2015, The New England journal of medicine.
[93] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[94] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[95] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] P. Park,et al. A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.
[97] D. Berry,et al. Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) , 2016 .
[98] M. Dowsett,et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] M. Espié,et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[100] T. Braun,et al. The Effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: A longitudinal study , 2018, The breast journal.
[101] R. Bast,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] B. Fisher,et al. National Surgical Adjuvant Breast and Bowel Project , 2020, Definitions.
[103] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[104] Early Breast Canc Trialists Collab. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011 .